October 16, 2020 – Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing.
The CTS Rotea system is the first Gibco instrument for cell therapy processing applications and facilitates workflows from research through GMP clinical development and commercial manufacturing.
The multifunctional and flexible CTS Rotea system can integrate into existing workflows, process low- to mid-range input volumes, and deliver low output volumes, Thermo Fisher Scientific says. Consisting of an instrument, closed sterile single use kit, and user programmable software, the CTS Rotea system provides processing flexibility to support a broad range of protocols for cell separation, washing and concentration with a cell recovery yield of greater than 95% while maintaining cell viability.
Using a modular, closed system for cell processing enables time-consuming processes to be decoupled from rapid processes, improving facility and equipment utilization and reducing the capital investment required, the company said. Use of the same system from research through process development and commercial manufacturing lowers the risk of process delays associated with changing systems. Sterile, closed, single-use kits enable cell processing in grade C clean rooms, leading to cost-effective transfer and scale-out of processes.